CN1927205A - 阿戈美拉汀与去甲肾上腺素重摄取抑制剂的新联合以及包含该联合的药物组合物 - Google Patents
阿戈美拉汀与去甲肾上腺素重摄取抑制剂的新联合以及包含该联合的药物组合物 Download PDFInfo
- Publication number
- CN1927205A CN1927205A CNA2006101289194A CN200610128919A CN1927205A CN 1927205 A CN1927205 A CN 1927205A CN A2006101289194 A CNA2006101289194 A CN A2006101289194A CN 200610128919 A CN200610128919 A CN 200610128919A CN 1927205 A CN1927205 A CN 1927205A
- Authority
- CN
- China
- Prior art keywords
- agomelatine
- reuptake inhibitor
- anxiety
- depression
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及包含阿戈美拉汀或N－[2－(7－甲氧基－1－萘基)乙基]乙酰胺与去甲肾上腺素重摄取抑制剂的联合以及含有所述联合的药物。
Description
以及包含该联合的药物组合物
技术领域：
本发明涉及式(I)的阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺或其水合物、晶体形式和可药用酸或碱的加成盐与去甲肾上腺素重摄取抑制剂或在细胞外水平能够提高去甲肾上腺素浓度的任何药物的新联合，
用于获得用于治疗抑郁症、更特别是用于治疗难治性抑郁症(resistantdepressions)的药物组合物。
背景技术：
阿戈美拉汀，或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺，具有褪黑激素能系统受体激动剂和5-HT2C受体拮抗剂的双重特征。这些特征使得它在中枢神经系统中具有活性，更特别是在重症抑郁、季节性情感障碍、睡眠障碍、心血管疾病、消化系统疾病、由时差导致的失眠和疲劳、食欲紊乱和肥胖症的治疗中有活性。
欧洲专利说明书EP 0447285中已经描述了阿戈美拉汀、其制备方法和在治疗中的用途。
发明内容：
现在，本申请人已经发现阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺或其水合物、晶体形式和可药用酸或碱的加成盐与去甲肾上腺素重摄取抑制剂的联合具有有价值的特性，该特性允许其用于治疗重症抑郁、季节性情感障碍和更特别是用于治疗难治性抑郁症以及用于治疗与心境障碍有关的精神病合并发病(co-morbidity)：焦虑、恐慌、紧张、睡眠障碍…。
中枢神经系统紊乱，例如抑郁和焦虑，影响大量所有年龄段的人。尽管在该领域中存在很多有效的分子，但是无一可完全治愈那些不同的病理状态，并且其中一些具有显著的副作用。因此，一直在研发新的可选治疗并且不断成为必需。这对于对所有治疗完全有抗性的患者而言尤其如此。常规的所谓“联合策略”包括将多种具有不同作用机制的治疗合并以获得阳性作用。通常，所观察到的有益作用是患者依赖性的，由对联合的一种或另一种化合物的响应引起。
文献中描述的最常规的联合涉及与心境稳定剂如锂、与具有不同临床性质或不同神经化学性质的其它抗抑郁剂的联合。
现在，申请人已经令人惊讶地发现阿戈美拉汀的作用可以被去甲肾上腺素重摄取抑制剂或在细胞外水平能够提高去甲肾上腺素浓度的药物加强。那些药物具有加强阿戈美拉汀作用的特征。
这种不可预知的作用允许考虑将联合用于治疗重症抑郁、季节性情感障碍和更特别是用于治疗难治性抑郁症以及与心境障碍有关的精神病合并发病：焦虑、恐慌、紧张和睡眠障碍。甚至更特别而言，作用的加强允许本发明的联合用于治疗对所有治疗有抗性的患者。
在本发明的去甲肾上腺素重摄取抑制剂中，可更特别地且无任何限制意义地提及的是瑞波西汀和地昔帕明。
根据本发明优选的去甲肾上腺素重摄取抑制剂为瑞波西汀。
因此，本发明涉及阿戈美拉汀或其水合物、晶体形式和可药用酸或碱的加成盐与去甲肾上腺素重摄取抑制剂化合物或在细胞外水平能够提高去甲肾上腺素浓度的化合物的联合在获得用于治疗重症抑郁、季节性情感障碍和更特别是难治性抑郁症以及治疗与心境障碍有关的精神病合并发病：焦虑、恐慌、紧张、睡眠障碍的药物组合物中的用途。
本发明还涉及包含阿戈美拉汀或其水合物、晶体形式和可药用酸或碱的加成盐与去甲肾上腺素重摄取抑制剂化合物或在细胞外水平能够提高去甲肾上腺素浓度的化合物的联合以及一种或多种可药用赋形剂的药物组合物。
在本发明的药物组合物中，可更特别提及的是适于经口服、胃肠道外或经鼻给药的那些，例如片剂或糖衣锭、舌下片、明胶胶囊、锭剂、栓剂、乳膏剂、软膏剂、皮肤凝胶等等。
除了阿戈美拉汀和去甲肾上腺素重摄取抑制剂化合物之外，本发明的药物组合物还包含一种或多种选自稀释剂、润滑剂、粘合剂、崩解剂、吸收剂、着色剂、甜味剂等等的赋形剂或载体。以举例方式且无任何限制意义可被提及的有：
◆稀释剂：乳糖、葡萄糖、蔗糖、甘露醇、山梨醇、纤维素、甘油，
◆润滑剂：二氧化硅、滑石粉、硬脂酸及其镁盐和钙盐、聚乙二醇，
◆粘合剂：硅酸镁铝、淀粉、明胶、黄芪胶、甲基纤维素、羧甲基纤维素钠和聚乙烯吡咯烷酮，
◆崩解剂：琼脂、海藻酸及其钠盐、泡腾混合物。
有用剂量根据患者的性别、年龄及体重、给药途径、紊乱的性质以及任何所联合的治疗的不同而不同，为每24小时1mg至50mg阿戈美拉汀，更优选为每天25mg。去甲肾上腺素重摄取抑制剂的剂量将低于其单独给药时所用的剂量。
具体实施方式：
药物组合物：
制备1000片片剂的处方，每片包含25mg活性成分：
N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺……………………………25g
乳糖一水合物……………………………………………………… 62g
硬脂酸镁…………………………………………………………… 1.3g
聚维酮……………………………………………………………… 9g
无水胶态二氧化硅………………………………………………… 0.3g
纤维素羟乙酸钠………………………………………………… 30g
硬脂酸…………………………………………………………… 2.6g
临床研究
临床研究在重症抑郁患者中进行，所述患者用阿戈美拉汀和安慰剂或者用阿戈美拉汀和瑞波西汀治疗6周。所用诊断系统是DSM-IV；效力的主要标准是汉密尔顿抑郁分级量表(Hamilton Rating Scale for Depression)的总评分。进行不期望事件的汇编。研究表明阿戈美拉汀和瑞波西汀的联合比单独的阿戈美拉汀具有更高的活性。
Claims (5)
1.阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺或其水合物、晶体形式和可药用酸或碱的加成盐与去甲肾上腺素重摄取抑制剂或在细胞外水平允许提高去甲肾上腺素浓度的药物的联合。
2.根据权利要求1的联合，其中去甲肾上腺素重摄取抑制剂是瑞波西汀。
3.药物组合物，包含作为活性成分的权利要求1或2的阿戈美拉汀或其水合物、晶体形式和可药用酸或碱的加成盐与去甲肾上腺素重摄取抑制剂的联合，单独或与一种或多种可药用赋形剂组合。
4.根据权利要求3的药物组合物，用于生产治疗重症抑郁、季节性情感障碍和更特别是难治性抑郁症以及治疗与心境障碍有关的精神病合并发病：焦虑、恐慌、紧张、睡眠障碍的药物。
5.权利要求1或2的联合在获得用于治疗重症抑郁、季节性情感障碍和更特别是难治性抑郁症以及治疗与心境障碍有关的精神病合并发病：焦虑、恐慌、紧张、睡眠障碍的药物组合物中的用途。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0509206A FR2890564B1 (fr) | 2005-09-09 | 2005-09-09 | Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent |
| FR0509206 | 2005-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1927205A true CN1927205A (zh) | 2007-03-14 |
Family
ID=36190808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101289194A Pending CN1927205A (zh) | 2005-09-09 | 2006-09-04 | 阿戈美拉汀与去甲肾上腺素重摄取抑制剂的新联合以及包含该联合的药物组合物 |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US7622505B2 (zh) |
| EP (1) | EP1769798B1 (zh) |
| JP (2) | JP5395998B2 (zh) |
| KR (1) | KR100863384B1 (zh) |
| CN (1) | CN1927205A (zh) |
| AP (1) | AP2615A (zh) |
| AR (1) | AR056056A1 (zh) |
| AT (1) | ATE404205T1 (zh) |
| AU (1) | AU2006209368B2 (zh) |
| BR (1) | BRPI0603759A (zh) |
| CA (1) | CA2558782C (zh) |
| CY (1) | CY1108319T1 (zh) |
| DE (1) | DE602006002210D1 (zh) |
| DK (1) | DK1769798T3 (zh) |
| EA (1) | EA011650B1 (zh) |
| ES (1) | ES2313590T3 (zh) |
| FR (1) | FR2890564B1 (zh) |
| GE (1) | GEP20094742B (zh) |
| GT (1) | GT200600408A (zh) |
| HR (1) | HRP20080535T3 (zh) |
| JO (1) | JO2521B1 (zh) |
| MA (1) | MA28505B1 (zh) |
| ME (2) | ME02767B (zh) |
| MX (1) | MXPA06010157A (zh) |
| MY (1) | MY142260A (zh) |
| NO (1) | NO338029B1 (zh) |
| NZ (1) | NZ549725A (zh) |
| PE (1) | PE20070429A1 (zh) |
| PL (1) | PL1769798T3 (zh) |
| PT (1) | PT1769798E (zh) |
| RS (1) | RS50631B (zh) |
| SA (1) | SA06270308B1 (zh) |
| SG (1) | SG131030A1 (zh) |
| SI (1) | SI1769798T1 (zh) |
| TW (1) | TWI324513B (zh) |
| UA (1) | UA83542C2 (zh) |
| UY (1) | UY29778A1 (zh) |
| WO (1) | WO2007028904A1 (zh) |
| ZA (1) | ZA200607562B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342924A (zh) * | 2010-08-05 | 2012-02-08 | 北京本草天源药物研究院 | 一种含有阿戈美拉汀的药物组合物 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4642134B2 (ja) * | 2007-05-01 | 2011-03-02 | コンサート ファーマシューティカルズ インコーポレイテッド | ナフチル（エチル）アセトアミド |
| WO2008141033A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals Inc. | Substituted naphthalenes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ZA985765B (en) * | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| ZA989251B (en) * | 1997-10-17 | 2000-04-10 | Lilly Co Eli | Potentiation of pharmaceuticals. |
| FR2834890B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'agomelatine |
| JP2005518439A (ja) * | 2002-02-26 | 2005-06-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬 |
| JP2004292445A (ja) * | 2003-03-11 | 2004-10-21 | Katsunori Nonogaki | 糖尿病治療薬 |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| BRPI0414347A (pt) * | 2003-09-12 | 2006-11-07 | Warner Lambert Co | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade |
-
2005
- 2005-09-09 FR FR0509206A patent/FR2890564B1/fr not_active Expired - Fee Related
-
2006
- 2006-08-22 MA MA29281A patent/MA28505B1/fr unknown
- 2006-08-31 EA EA200601410A patent/EA011650B1/ru not_active IP Right Cessation
- 2006-08-31 UY UY29778A patent/UY29778A1/es not_active Application Discontinuation
- 2006-08-31 SG SG200605974-5A patent/SG131030A1/en unknown
- 2006-09-04 CN CNA2006101289194A patent/CN1927205A/zh active Pending
- 2006-09-04 PE PE2006001067A patent/PE20070429A1/es not_active Application Discontinuation
- 2006-09-06 BR BRPI0603759-3A patent/BRPI0603759A/pt not_active Application Discontinuation
- 2006-09-06 SA SA06270308A patent/SA06270308B1/ar unknown
- 2006-09-07 NZ NZ549725A patent/NZ549725A/en not_active IP Right Cessation
- 2006-09-07 MY MYPI20064102A patent/MY142260A/en unknown
- 2006-09-07 US US11/516,877 patent/US7622505B2/en not_active Expired - Fee Related
- 2006-09-07 MX MXPA06010157A patent/MXPA06010157A/es active IP Right Grant
- 2006-09-07 JO JO2006305A patent/JO2521B1/en active
- 2006-09-07 GE GEAP20069612A patent/GEP20094742B/en unknown
- 2006-09-08 UA UAA200609700A patent/UA83542C2/uk unknown
- 2006-09-08 NO NO20064048A patent/NO338029B1/no not_active IP Right Cessation
- 2006-09-08 SI SI200630102T patent/SI1769798T1/sl unknown
- 2006-09-08 AT AT06291421T patent/ATE404205T1/de active
- 2006-09-08 DE DE602006002210T patent/DE602006002210D1/de active Active
- 2006-09-08 EP EP06291421A patent/EP1769798B1/fr active Active
- 2006-09-08 GT GT200600408A patent/GT200600408A/es unknown
- 2006-09-08 CA CA2558782A patent/CA2558782C/fr not_active Expired - Fee Related
- 2006-09-08 ME MEP-2008-504A patent/ME02767B/me unknown
- 2006-09-08 DK DK06291421T patent/DK1769798T3/da active
- 2006-09-08 AP AP2008004378A patent/AP2615A/xx active
- 2006-09-08 ME MEP-2008-631A patent/ME02758B/me unknown
- 2006-09-08 RS RSP-2008/0504A patent/RS50631B/sr unknown
- 2006-09-08 ES ES06291421T patent/ES2313590T3/es active Active
- 2006-09-08 AR ARP060103907A patent/AR056056A1/es not_active Application Discontinuation
- 2006-09-08 AU AU2006209368A patent/AU2006209368B2/en not_active Ceased
- 2006-09-08 PL PL06291421T patent/PL1769798T3/pl unknown
- 2006-09-08 ZA ZA200607562A patent/ZA200607562B/xx unknown
- 2006-09-08 TW TW095133159A patent/TWI324513B/zh not_active IP Right Cessation
- 2006-09-08 WO PCT/FR2006/002067 patent/WO2007028904A1/fr active Application Filing
- 2006-09-08 PT PT06291421T patent/PT1769798E/pt unknown
- 2006-09-11 JP JP2006245009A patent/JP5395998B2/ja not_active Expired - Fee Related
- 2006-09-11 KR KR1020060087622A patent/KR100863384B1/ko active IP Right Grant
-
2008
- 2008-09-04 CY CY20081100955T patent/CY1108319T1/el unknown
- 2008-11-05 HR HR20080535T patent/HRP20080535T3/xx unknown
-
2010
- 2010-12-21 JP JP2010284300A patent/JP2011088919A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342924A (zh) * | 2010-08-05 | 2012-02-08 | 北京本草天源药物研究院 | 一种含有阿戈美拉汀的药物组合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1927193A (zh) | 阿戈美拉汀在获得用于治疗抑郁患者睡眠障碍的药物中的用途 | |
| CN101049290A (zh) | 阿戈美拉汀在制备用于治疗广泛性焦虑症的药物中的用途 | |
| JP2012197304A (ja) | ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用 | |
| CN1927205A (zh) | 阿戈美拉汀与去甲肾上腺素重摄取抑制剂的新联合以及包含该联合的药物组合物 | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| ES2390225T3 (es) | Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión | |
| JP2007503424A (ja) | 抗炎症剤として有用なα−アミノアミド誘導体 | |
| CN101194901A (zh) | 阿戈美拉汀在制备用于治疗Smith-Magenis综合征的药物中的用途 | |
| CN1927194A (zh) | 阿戈美拉汀与精神调节剂的新联合以及包含该联合的药物组合物 | |
| EP4340941A2 (en) | Drugs for treating neurodevelopmental disorders | |
| JP2009013074A (ja) | 全般性不安障害の処置を目的とする医薬を得るためのアゴメラチンの使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1100204 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20070314 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1100204 Country of ref document: HK |